These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27737809)

  • 1. In vitro and in silico characterisation of Tacrolimus released under biorelevant conditions.
    Mercuri A; Wu S; Stranzinger S; Mohr S; Salar-Behzadi S; Bresciani M; Fröhlich E
    Int J Pharm; 2016 Dec; 515(1-2):271-280. PubMed ID: 27737809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of in vivo drug performance using in vitro dissolution coupled with STELLA: a study with selected drug products.
    Chakraborty S; Yadav L; Aggarwal D
    Drug Dev Ind Pharm; 2015; 41(10):1667-73. PubMed ID: 25494535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biorelevant dissolution media as a predictive tool for glyburide a class II drug.
    Wei H; Löbenberg R
    Eur J Pharm Sci; 2006 Sep; 29(1):45-52. PubMed ID: 16815694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound.
    Kou D; Zhang C; Yiu H; Ng T; Lubach JW; Janson M; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
    Mol Pharm; 2018 Apr; 15(4):1607-1617. PubMed ID: 29522347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach.
    Otsuka K; Wagner C; Selen A; Dressman J
    J Pharm Pharmacol; 2015 May; 67(5):651-65. PubMed ID: 25644429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
    Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products.
    Okumu A; DiMaso M; Löbenberg R
    Eur J Pharm Biopharm; 2009 May; 72(1):91-8. PubMed ID: 19056493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of food effect on the oral absorption of clarithromycin from immediate release tablet using physiological modelling.
    Radwan A; Jayyousi R; Shraim N; Zaid AN
    Biopharm Drug Dispos; 2019 Apr; 40(3-4):121-134. PubMed ID: 30891805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining in vitro and in silico methods for better prediction of surfactant effects on the absorption of poorly water soluble drugs-a fenofibrate case example.
    Berthelsen R; Sjögren E; Jacobsen J; Kristensen J; Holm R; Abrahamsson B; Müllertz A
    Int J Pharm; 2014 Oct; 473(1-2):356-65. PubMed ID: 24997410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing Quantitative In Vitro-In Vivo Correlation for Fenofibrate Immediate-Release Formulations With the Biphasic Dissolution-Partition Test Method.
    Xu H; Shi Y; Vela S; Marroum P; Gao P
    J Pharm Sci; 2018 Jan; 107(1):476-487. PubMed ID: 28666964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of the Oral Pharmacokinetics and Food Effects of Gabapentin Enacarbil Extended-Release Tablets Using Biorelevant Dissolution Tests.
    Yamaguchi Ikeuchi S; Kambayashi A; Kojima H; Oku N; Asai T
    Biol Pharm Bull; 2018; 41(11):1708-1715. PubMed ID: 30381671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro solubility, dissolution and permeability studies combined with semi-mechanistic modeling to investigate the intestinal absorption of desvenlafaxine from an immediate- and extended release formulation.
    Franek F; Jarlfors A; Larsen F; Holm P; Steffansen B
    Eur J Pharm Sci; 2015 Sep; 77():303-13. PubMed ID: 26091569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can in vitro/in silico tools improve colonic concentration estimations for oral extended-release formulations? A case study with upadacitinib.
    Favaron A; Hens B; Camotti Montanha M; McAllister M; Tomaszewska I; Moustafa S; de Oliveira MA; Basit AW; Orlu M
    J Control Release; 2024 Jun; 370():182-194. PubMed ID: 38641022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically Based Biopharmaceutics Model of Vildagliptin Modified Release (MR) Tablets to Predict In Vivo Performance and Establish Clinically Relevant Dissolution Specifications.
    Madny MA; Deshpande P; Tumuluri V; Borde P; Sangana R
    AAPS PharmSciTech; 2022 Apr; 23(4):108. PubMed ID: 35386066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case study on the in silico absorption simulations of levothyroxine sodium immediate-release tablets.
    Kocic I; Homsek I; Dacevic M; Grbic S; Parojcic J; Vucicevic K; Prostran M; Miljkovic B
    Biopharm Drug Dispos; 2012 Apr; 33(3):146-59. PubMed ID: 22374714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A physiologically-based drug absorption modeling for orally disintegrating tablets.
    Kambayashi A; Kiyota T
    Eur J Pharm Biopharm; 2020 Jul; 152():1-9. PubMed ID: 32371153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.